TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced today that a platform presentation of an abstract titled 'Isomyosamine for the Treatment of Sarcopenia in Older Adults' was delivered by Mitchell Glass, M.D., President and Chief Medical Officer of TNF, at the British Geriatrics Society (BGB) Spring Meeting 2025, held April 9-11, 2025, in Belfast, Ireland and online.
During his presentation, Dr. Glass spoke about the Company's small-molecule TNF-alpha (TNF-α) inhibitor, isomyosamine, which has shown potential for regulating pro-inflammatory cytokines associated with sarcopenia. In response to a question, he emphasized the Company's commitment to sarcopenia as an initial indication, including muscle wasting as an effect of treatment with GLP-1 agonists. He also commented on the Company's plans to extend Phase 3 into the UK and Europe.
'An earlier Phase 2 study of isomyosamine demonstrated its safety and tolerability in elderly patients with sarcopenia, with significant reductions in inflammatory biomarkers such as TNF-α, IL-6, and soluble TNF receptor 1 (sTNFR1). We are currently enrolling patients in a larger Phase 2b clinical trial that will investigate isomyosamine's effect on cellular inflammation and recovery of ambulation speed in elderly patients post-hip fracture. An increased sample size and more frequent dosing in the follow-up trial will enable us to better evaluate the drug's potential to improve both clinical and biochemical outcomes in sarcopenic patients,' Dr. Glass explained.
The British Geriatrics Society is the membership association for professionals specializing in the healthcare of older people across the UK. Founded in 1947, BGS has over 5,000 members, and it is the only Society in the UK offering specialist expertise in the wide range of healthcare needs of older people.
About Isomyosamine
Isomyosamine (ICD-10-CM code M62.84) is a novel plant alkaloid small molecule shown to regulate the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines including TNF-alpha (TNF-α), an immune cell signaling protein and inflammatory cytokine responsible for inducing and maintaining the inflammatory process. TNF-α is located upstream of a cascade of molecular signals that induces inflammation and helps activate the process of aging. Many in vivo and in vitro studies have shown that TNFα plays a causative role in the pathogenesis of various age-related diseases.
About TNF Pharmaceuticals, Inc.
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit www.tnfpharma.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the Company's ability to launch and the timing of the Company's planned trial of isomyosamine as a treatment for GLP-1-induced sarcopenia and frailty. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250416886460/en/
CONTACT: Investor Contact:Robert Schatz
(646) 421-9523
[email protected]
www.tnfpharma.com
KEYWORD: NORTH AMERICA UNITED STATES IRELAND UNITED KINGDOM EUROPE MARYLAND
INDUSTRY KEYWORD: RESEARCH SENIORS CLINICAL TRIALS OTHER HEALTH BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL CONSUMER HEALTH SCIENCE
SOURCE: TNF Pharmaceuticals, Inc.
Copyright Business Wire 2025.
PUB: 04/16/2025 09:15 AM/DISC: 04/16/2025 09:16 AM
http://www.businesswire.com/news/home/20250416886460/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Discovering Undiscovered Gems in the US Market August 2025
As the U.S. stock market navigates through a period of mixed performance with the Dow Jones Industrial Average reaching new highs while the S&P 500 and Nasdaq face declines, investors are keenly observing potential shifts in Federal Reserve policies that could impact future market dynamics. In this environment, identifying stocks with strong fundamentals and growth potential becomes crucial, especially as major indices fluctuate and economic indicators remain uncertain. Top 10 Undiscovered Gems With Strong Fundamentals In The United States Name Debt To Equity Revenue Growth Earnings Growth Health Rating Southern Michigan Bancorp 117.38% 8.87% 4.89% ★★★★★★ Oakworth Capital 87.50% 15.82% 9.79% ★★★★★★ ASA Gold and Precious Metals NA 12.79% -0.59% ★★★★★★ Sound Financial Bancorp 34.70% 2.11% -11.08% ★★★★★★ Metalpha Technology Holding NA 75.66% 28.60% ★★★★★★ First Northern Community Bancorp NA 8.05% 12.27% ★★★★★★ Senstar Technologies NA -20.82% 14.32% ★★★★★★ Valhi 44.30% 1.10% -1.40% ★★★★★☆ Pure Cycle 5.02% 4.35% -2.25% ★★★★★☆ Rich Sparkle Holdings 26.73% -6.13% 1.75% ★★★★★☆ Click here to see the full list of 286 stocks from our US Undiscovered Gems With Strong Fundamentals screener. Let's review some notable picks from our screened stocks. Carter Bankshares Simply Wall St Value Rating: ★★★★☆☆ Overview: Carter Bankshares, Inc. is the bank holding company for Carter Bank & Trust, offering a range of retail and commercial banking products and insurance services in the United States, with a market capitalization of $414.86 million. Operations: Carter Bankshares generates revenue primarily from its banking segment, totaling $153.12 million. Carter Bankshares, with assets totaling US$4.8 billion and equity of US$405.6 million, has been making waves recently. The company reported a significant earnings growth of 152.5% over the past year, outperforming the industry average of 12.5%. Despite this impressive performance, it grapples with a high level of bad loans at 6.7%, coupled with an insufficient allowance for bad loans at 28%. Recently added to multiple Russell indexes and completing a share buyback worth US$10.41 million for 171,899 shares, CARE seems poised for continued attention in investment circles due to its strong earnings momentum and strategic moves. Delve into the full analysis health report here for a deeper understanding of Carter Bankshares. Learn about Carter Bankshares' historical performance. Northrim BanCorp Simply Wall St Value Rating: ★★★★★★ Overview: Northrim BanCorp, Inc. is the bank holding company for Northrim Bank, offering commercial banking products and services to businesses and professional individuals, with a market cap of $476.66 million. Operations: Northrim BanCorp generates revenue primarily through its Community Banking segment with $121.89 million, followed by Home Mortgage Lending at $35.57 million and Specialty Finance contributing $6.39 million. Northrim BanCorp, with assets totaling US$3.2 billion and equity of US$290.2 million, stands out for its robust financial health. The company boasts total deposits of US$2.8 billion against loans of US$2.2 billion, indicating a solid funding base primarily from customer deposits—considered low risk compared to external borrowing. Its allowance for bad loans is sufficient at 190%, covering non-performing loans which are just 0.5% of total loans, well within acceptable limits. Recent earnings growth was impressive at 39%, far surpassing the industry average of 12%. Northrim's inclusion in multiple Russell indices highlights its recognition as a promising player in the market landscape. Get an in-depth perspective on Northrim BanCorp's performance by reading our health report here. Examine Northrim BanCorp's past performance report to understand how it has performed in the past. Shore Bancshares Simply Wall St Value Rating: ★★★★★★ Overview: Shore Bancshares, Inc. functions as a bank holding company for Shore United Bank, N.A., with a market capitalization of $525.66 million. Operations: Shore Bancshares generates revenue primarily from its community banking segment, which reported $208.21 million. Shore Bancshares, with total assets of US$6.0 billion and equity of US$565.2 million, presents a robust financial profile. Its net interest margin stands at 3.1%, supported by total deposits of US$5.3 billion and loans amounting to US$4.8 billion. The bank maintains a sufficient allowance for bad loans at 344% coverage, with non-performing loans at just 0.3%. Trading at a price-to-earnings ratio of 9.9x, it offers good value compared to the broader market's 18.8x average, while its earnings growth last year outpaced the industry significantly by reaching an impressive 166%. Dive into the specifics of Shore Bancshares here with our thorough health report. Gain insights into Shore Bancshares' past trends and performance with our Past report. Key Takeaways Take a closer look at our US Undiscovered Gems With Strong Fundamentals list of 286 companies by clicking here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Seeking Other Investments? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CARE NRIM and SHBI. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
33 minutes ago
- Yahoo
Viking Therapeutics stock falls 37% on high dropout rate in obesity trial
-- Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) shares gained 1.5% as analysts pointed to competitive advantages. The trial demonstrated that Viking's oral tablet formulation of VK2735, a dual GLP-1 and GIP receptor agonist, met its primary endpoint with patients losing up to 12.2% of body weight after 13 weeks compared to 1.3% for placebo. Despite the weight loss efficacy, the 28% treatment discontinuation rate among patients receiving VK2735 versus 18% for placebo raised significant concerns among investors and analysts. Mizuho analyst Jared Holz highlighted competitive disadvantages compared to Eli Lilly's offerings: "Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range --- but over 72-weeks; A much longer trial, and therefor LLY looks far better head-to-head. This probably shutters hope for VKTX a bigtime player in the oral obesity market over the near to medium term." JPMorgan (NYSE:JPM) analyst Hardik Parikh offered a more balanced view, noting, "In 13 weeks, the three highest-dosing arms of 60/90/120mg showed avg pbo-adj weight loss of ~7.5%, 10%, 11%, which we think is very strong compared with other orals in development. Tolerability overall was manageable, but it was worse than we expected based on the ph1 performance." Parikh added that while the adverse event profile wasn't as clean as in Phase 1 trials, "we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile." Viking reported that 99% of gastrointestinal-related adverse events were mild or moderate. The company also highlighted an exploratory maintenance dosing arm showing weight loss could be maintained at lower doses. The major adverse events included vomiting rates of 20-35% in the three highest dose arms compared to about 10% for placebo, and nausea rates of approximately 58% for patients on treatment versus 48% for placebo. Related articles Viking Therapeutics stock falls 37% on high dropout rate in obesity trial Tesla robotaxi trial impresses, pricing power clear: William Blair Palo Alto Networks gains after strong earnings and Bank of America upgrade
Yahoo
34 minutes ago
- Yahoo
Is Most-Watched Stock JD.com, Inc. (JD) Worth Betting on Now?
Inc. (JD) is one of the stocks most watched by visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this company have returned -4.9%, compared to the Zacks S&P 500 composite's +2.5% change. During this period, the Zacks Internet - Commerce industry, which falls in, has gained 2.3%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Revisions to Earnings Estimates Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. is expected to post earnings of $0.40 per share for the current quarter, representing a year-over-year change of -67.7%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged. For the current fiscal year, the consensus earnings estimate of $2.49 points to a change of -41.6% from the prior year. Over the last 30 days, this estimate has changed +0.3%. For the next fiscal year, the consensus earnings estimate of $3.61 indicates a change of +45.2% from what is expected to report a year ago. Over the past month, the estimate has changed +0.3%. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #5 (Strong Sell) for The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial. In the case of the consensus sales estimate of $40.08 billion for the current quarter points to a year-over-year change of +8%. The $183.33 billion and $192.78 billion estimates for the current and next fiscal years indicate changes of +14% and +5.2%, respectively. Last Reported Results and Surprise History reported revenues of $49.79 billion in the last reported quarter, representing a year-over-year change of +24.2%. EPS of $0.69 for the same period compares with $1.29 a year ago. Compared to the Zacks Consensus Estimate of $46.93 billion, the reported revenues represent a surprise of +6.1%. The EPS surprise was +38%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period. Valuation No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade. Conclusion The facts discussed here and much other information on might help determine whether or not it's worthwhile paying attention to the market buzz about However, its Zacks Rank #5 does suggest that it may underperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (JD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
